From Lipid Sciences (LIPD) we learned about what could be a fascinating approach that creates a high concentration of a modified form of HDL (good cholesterol). This modified form is known to be more effective in reverse cholesterol transport - the body's natural process for removing lipids from arterial plaque.

Data about the delipidation procedure were presented at Cardiovascular Revascularization Therapies: CRT 2007 Symposium. The conference highlighted the scientific basis Lipid Sciences’ proprietary HDL Selective Delipidation process. This process is currently being evaluated at the Washington Hospital Center (WHC).

The Process

Lipid Sciences' proprietary "Selective Delipdation" process is applied to samples of human plasma. It has successfully transformed alpha HDL into pre-beta HDL, which demonstrated it selectively remove lipids from lipid-filled cells commonly found in arterial plaque associated with atherosclerosis. Lipid Sciences’ delipidated plasma was shown to contain approximately 28 times more pre-beta HDL than the undelipidated (control) plasma. Good news is that the lipids are removed from only the targeted HDL particles without significantly altering LDL or any other plasma lipoproteins. As a result, it transformed the less active alpha HDL into the scavenger, or pre-beta, HDL with no significant impact observed on other lipoproteins' composition or metabolism. 78% of the HDL cholesterol was removed from the plasma samples, and 95% of the critical apolipoprotein A-I was preserved.

The delipidated HDL created was shown to be significantly more effective in removing cholesterol from cells than the unprocessed plasma, even exceeding the efflux capability of apolipoprotein A-I.

Clinical trial at the WHC is currently ongoing to evaluate the Safety of its HDL Selective Depilidation System, PDS-2, in Subjects with Acute Coronary Syndrome (ACS). To date, 82 patients have consented to be part of this trial and 14 patients have met the stringent inclusion criteria and have been enrolled. All plasma infusions are said to have been well tolerated and the Data Safety and Monitoring Committee has authorized the continuation of the clinical trial after review of the patient safety data to date.

Lipid Sciences' HDL Selective Delipidation technology is a potentially radical approach to treating heart disease. The firm believes it prevents the rupture of vulnerable plaque and, hence, stops the patient's next heart attack or stroke.

The firm anticipates concluding this trial during the second half of 2007 and plans to initiate a follow-on effectiveness trial in early 2008. According to the firm, statistics show that 80% of Acute Coronary Syndrome patients have one or more ruptured plaques in addition to the culprit lesion that brought them to the hospital initially. More than 1 in 5 of these patients will experience a second coronary event within 24 months. Lipid Sciences believes its HDL Selective Delipidation therapy could have a profound impact on the treatment regimen of cardiovascular disease in this critical patient population.

Lipid Sciences believes it is well positioned to develop two new therapeutic tools for the cardiology community -- a medical device and an HDL Mimetic Peptide -- both intended to enhance the reverse cholesterol transport process with the goal of plaque regression in the coronary arteries. As a matter of fact, the firm declared it has begun working on the HDL Mimetic Peptide program. The target market for this therapy is also the acute coronary syndrome (ACS) patient. This synthetic "HDL in a bottle" is expected to enhance the body's naturally occurring reverse cholesterol transport process. If successful, it will mimic the biological activity of HDL to regress plaque and reduce inflammation. Lipid Sciences' HDL Mimetic Peptide is designed for cost-effective delivery as an infusion therapy.

Data supporting this CRT 2007 presentation is posted in the Investor Relations section of our website at www.lipidsciences.com. In addition, an animated version of Lipid Sciences' HDL Selective Delipidation process can be viewed in the Technology section of the website.

Prohost is independent publication providing information on biotech companies. Prohost does not accept compensation from companies that are featured or profiled.It is strongly recommended that any purchase or sale decisions to any of the featured companies be discussed with a financial advisor or broker prior to completing any such purchase or sale decision.All statements or expressions are the opinion of Prohost and are not meant to be a solicitation or recommendation to buy, sell, or hold securities. Investing in embryonic companies, micro-capand growth securities is highly speculative and carries a high degree of risk. It is possible that an investor can lose all of his/her investment in this type of companies that are profiled. The information that Prohost relies on is either through the profiled company, news services, research reports, interviews, or other outside sources that Prohost believes are reliable.Prohost makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure of the profiled companies and accepts no responsibilities for inaccuracies or misleading content in any material supplied by those clients.There can be no assurance that future events relating to the profiled company will occur as anticipated.The information contained herein is provided as an information service only.Past performance of featured companies does not guarantee the future success of any currently featured or profiled company.We encourage our readers to invest carefully and read the investor information provided by the Securities and Exchange Commission ("SEC")and/or the National Association of Securities Dealers ("NASD")We also strongly recommend that you read theSEC advisory to investors concerning Internet Stock Fraud, which can be found at: http://www.sec.gov/consumer/cyberfr.htm.

Some biotechnology firms are crossing the borders into the future. These firms have raised the bar of the current technological potential to a much higher level. We decided to bring the promising firms to our subscribers’ attention.